Our study further demonstrates the immunogenicity of protein subunit vaccines against SARS-CoV-2 targeting the S1 subunit of the spike protein while also contributing insights on approaches to further increase the valency of currently approved COVID-19 vaccines. Here, PSMD1 is linked to COVID-19.